About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Omeros Corporation - Common Stock (NQ:OMER)

12.38 +0.41 (+3.43%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Omeros Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Omeros (OMER) Q1 2026 Earnings Transcript ↗
Omeros (OMER) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Omeros Q1 Earnings Call Highlights ↗
Omeros (NASDAQ:OMER) reported first-quarter 2026 net income of $56.1 million, or $0.78 per share, as the company began commercial sales of YARTEMLEA, its recently approved treatment for hematopoietic... 
Via MarketBeat
Topics Earnings
Omeros Corp (NASDAQ:OMER) Swings to Profit on YARTEMLEA Launch, Topping EPS Forecasts ↗
Via Chartmill
News headline image
Omeros Corporation Reports First Quarter 2026 Financial Results
From Omeros Corporation
Via Business Wire
Omeros Corp (NASDAQ:OMER) Reports Q4 2025 Earnings Boosted by Major Asset Sale, Launches First Commercial Product ↗
Via Chartmill
News headline image
Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026
From Omeros Corporation
Via Business Wire
News headline image
Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)
From Omeros Corporation
Via Business Wire
These stocks are gapping in today's session ↗
Via Chartmill
News headline image
Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026
From Omeros Corporation
Via Business Wire
News headline image
Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment
From Omeros Corporation
Via Business Wire
News headline image
Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program
From Omeros Corporation
Via Business Wire
News headline image
Omeros Announces First Commercial Sales of YARTEMLEA®
From Omeros Corporation
Via Business Wire
News headline image
Nasdaq, S&P 500 Futures Dip As Investors Brace For Jobs Data, Tariff Ruling: Why NVDA, MSFT, AAPL, APLD, NIO Are On Traders' Radar Today ↗
Nvidia, Apple, Microsoft, and select biotech names dominated early market buzz. 
Via Stocktwits
Topics ETFs Government Stocks
News headline image
Why Did Omeros Stock Jump 5% In After-Hours Trading Today? ↗
Yartemlea shipments to wholesalers are expected in the third week of January. 
Via Stocktwits
News headline image
Omeros Announces New Date for YARTEMLEA® Approval Conference Call
From Omeros Corporation
Via Business Wire
News headline image
Why Omeros Stock Skyrocketed Today ↗
The company is on the brink of commercializing a unique medication. 
Via The Motley Fool
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
Let's have a look at what is happening on the US markets one hour before the close of the markets on Wednesday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
News headline image
Retail’s Christmas Eve Watchlist: Omeros, Nike, Citi, Dynavax And Agios Spark Most Market Chatter ↗
The stocks were tracked during the shortened Christmas Eve session across healthcare, consumer, and banking. 
Via Stocktwits
Topics ETFs Economy Stocks
News headline image
Top movers in Wednesday's session ↗
Looking for insights into the US markets in the middle of the day on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
Which stocks are gapping on Wednesday? ↗
Traders are paying attention to the gapping stocks in Wednesday's session. Let's dive into which stocks are experiencing notable gaps. 
Via Chartmill
News headline image
Omeros Stock Jumps Premarket After FDA Approves First Drug For Rare Transplant Complication — Retail Sees Big Upside ↗
The drug was approved for use in adults and children aged two years and older. 
Via Stocktwits
News headline image
FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA
From Omeros Corporation
Via Business Wire
News headline image
Omeros Stock Garners High Retail Attention Ahead Of FDA Verdict For Life-Saving Drug ↗
The FDA decision on Narsoplimab, its treatment for post–stem cell and bone marrow transplant complications, is officially due on December 26. 
Via Stocktwits
News headline image
Omeros Corp Sells Immune-System Drug To Novo Nordisk In $2.1B Deal — Retail Shifts Focus To Narsoplimab FDA Call ↗
Omeros received $240 million upfront, with total deal value reaching up to $2.1 billion. 
Via Stocktwits
Topics Intellectual Property
News headline image
Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros’ Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)
From Omeros Corporation
Via Business Wire
News headline image
Omeros (OMER) Q3 2025 Earnings Call Transcript ↗
Omeros (OMER) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Derivatives Earnings
News headline image
Legence, Cidara Therapeutics, Avadel Pharmaceuticals, Omeros And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.